Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

被引：2
|
作者：
Kao, Jui-Hung [1 ]
Huang, Hsin-Tuan [1 ]
Li, Ko-Jen [1 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 08期
关键词：
CYCLOPHOSPHAMIDE;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：780 / 781
页数：2
相关论文
共 50 条
  • [41] Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
    Vincent Cottin
    Fernando J. Martinez
    R. Gisli Jenkins
    John A. Belperio
    Hideya Kitamura
    Maria Molina-Molina
    Inga Tschoepe
    Carl Coeck
    Dirk Lievens
    Ulrich Costabel
    Respiratory Research, 23
  • [42] EFFICACY AND SAFETY OF NINTEDANIB IN US/CANADIAN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES: FURTHER ANALYSES OF THE INBUILD TRIAL
    Shapera, Shane
    Moua, Teng
    Nambiar, Anoop
    Morrison, Lake
    Kolb, Martin
    Schlenker-Herceg, Rozsa
    Conoscenti, Craig
    Goeldner, Rainer-Georg
    Rohr, Klaus
    Stowasser, Susanne
    Brown, Kevin
    CHEST, 2020, 158 (04) : 2613A - 2615A
  • [43] Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
    Matteson, Eric L.
    Kelly, Clive
    Distler, Joerg H. W.
    Hoffmann-Vold, Anna-Maria
    Seibold, James R.
    Mittoo, Shikha
    Dellaripa, Paul F.
    Aringer, Martin
    Pope, Janet
    Distler, Oliver
    James, Alexandra
    Schlenker-Herceg, Rozsa
    Stowasser, Susanne
    Quaresma, Manuel
    Flaherty, Kevin R.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 (06) : 1039 - 1047
  • [44] Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
    Cottin, Vincent
    Martinez, Fernando J.
    Jenkins, R. Gisli
    Belperio, John A.
    Kitamura, Hideya
    Molina-Molina, Maria
    Tschoepe, Inga
    Coeck, Carl
    Lievens, Dirk
    Costabel, Ulrich
    RESPIRATORY RESEARCH, 2022, 23 (01)
  • [45] Acute exacerbations of progressive-fibrosing interstitial lung diseases
    Kolb, Martin
    Bondue, Benjamin
    Pesci, Alberto
    Miyazaki, Yasunari
    Song, Jin Woo
    Bhatt, Nitin Y.
    Huggins, John T.
    Oldham, Justin M.
    Padilla, Maria L.
    Roman, Jesse
    Shapera, Shane
    EUROPEAN RESPIRATORY REVIEW, 2018, 27 (150):
  • [46] Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
    Brown, Kevin K.
    Inoue, Yoshikazu
    Flaherty, Kevin R.
    Martinez, Fernando J.
    Cottin, Vincent
    Bonella, Francesco
    Cerri, Stefania
    Danoff, Sonye K.
    Jouneau, Stephane
    Goeldner, Rainer-Georg
    Schmidt, Martin
    Stowasser, Susanne
    Schlenker-Herceg, Rozsa
    Wells, Athol U.
    RESPIROLOGY, 2022, 27 (04) : 294 - 300
  • [47] Genetic susceptibilty and manifestation of progressive fibrosing interstitial lung diseases
    Sterclova, Martina
    Sikorova, Katerina
    Petrek, Martin
    Vasakova, Martina
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [48] The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Instititial Lung Diseases: Subgroup with Autoimmune Diseases
    Bonella, F.
    Matteson, E.
    Kelly, C.
    Distler, J. H. W.
    Hoffmann-Vold, A.
    Seibold, J. R.
    Mittoo, S.
    Distler, O.
    Goeldner, R. G.
    Schlenker-Herceg, R.
    Stowasser, S.
    Quaresma, M.
    Flaherty, K. R.
    PNEUMOLOGIE, 2020, 74 : S61 - S62
  • [49] Nintedanib for interstitial lung diseases
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2019, 1 (03): : E143 - E143
  • [50] Nintedanib in children and adolescents with fibrosing interstitial lung diseases (vol 61, 2201512, 2023)
    Deterding, R.
    Young, L. R.
    DeBoer, E. M.
    Warburton, D.
    Cunningham, S.
    Schwerk, N.
    Flaherty, K. R.
    Brown, K. K.
    Dumistracel, M.
    Erhardt, E.
    Bertulis, J.
    Gahlemann, M.
    Stowasser, S.
    Griese, M.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (05)
12345